<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00519870</url>
  </required_header>
  <id_info>
    <org_study_id>KA04/127</org_study_id>
    <nct_id>NCT00519870</nct_id>
  </id_info>
  <brief_title>Losartan Therapy in Pulmonary Hypertension</brief_title>
  <official_title>Losartan Decreases Pulmonary Artery Pressure and Improves Exercise Capacity in Patients With Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baskent University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baskent University</source>
  <brief_summary>
    <textblock>
      In addition to being effective vasodilators, angiotensin-converting enzyme inhibitors (ACEIs)
      and angiotensin receptor blockers (ARBs) exert neurohumoral inhibitory actions, such as the
      inhibition of vascular remodeling and smooth muscle cell proliferation and the amelioration
      of endothelial dysfunction. These beneficial effects, render those agents appropriate for use
      in the treatment of pulmonary hypertension. However, data regarding the use of ACEIs or ARBs
      in the treatment of PHT are limited. In this study, efficacy of an ARB, losartan was compared
      with those of the calcium channel blocker, nifedipine in the treatment of pulmonary
      hypertension using echocardiographic, 6-minute walk test (6MWT), cardiopulmonary exercise
      test, and endothelin-1 levels.Losartan is as effective as nifedipine for reducing Doppler
      echocardiographically measured PAP and improving exercise capacity on 6MWT and CPET. However
      the short-term use of losartan or nifedipine had no statistically significant effect on
      endothelin-1 levels in patients with PHT.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date>July 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>I, II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>I: nifedipine II: losartan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nifedipine, losartan</intervention_name>
    <description>I: nifedipine 30 mg/d II: losartan 50 mg/d</description>
    <arm_group_label>I, II</arm_group_label>
    <other_name>nifedipine (Adalat Crono, Bayer AG, Leverkusen, Germany)</other_name>
    <other_name>losartan (Cozaar, Merck Sharp &amp; Dohme, Wilmington, DE, USA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>losartan</intervention_name>
    <description>II: losartan</description>
    <arm_group_label>I, II</arm_group_label>
    <other_name>losartan (Cozaar, Merck Sharp &amp; Dohme, Wilmington, DE, USA) 50 mg/d</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine, losartan</intervention_name>
    <description>I: nifedipine II: losartan</description>
    <arm_group_label>I, II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pulmonary hypertension diagnosed by Doppler echocardiographic examination (a mean
             pulmonary artery pressure of &gt; 26mmHg)

        Exclusion Criteria:

          -  acute infectious or inflammatory disease,

          -  exacerbation of chronic obstructive pulmonary disease,

          -  malignancy,

          -  acute coronary syndrome in the last 4 weeks,

          -  uncontrolled arrhythmia and hypertension,

          -  decompensated heart failure,

          -  acute pulmonary emboli,

          -  thrombus in a lower extremity,

          -  oxygen saturation below 85% at rest,

          -  failure to cooperate with CPET
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serife Savas Bozbas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baskent University Faculty of Medicine, Department of Pulmonary Disease</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fusun Oner Eyuboglu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Baskent University Faculty of Medicine, Department of Pulmonary Disease</affiliation>
  </overall_official>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2007</study_first_submitted>
  <study_first_submitted_qc>August 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2007</study_first_posted>
  <last_update_submitted>August 22, 2007</last_update_submitted>
  <last_update_submitted_qc>August 22, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2007</last_update_posted>
  <keyword>Pulmonary hypertension</keyword>
  <keyword>Angiotensin receptor blocker</keyword>
  <keyword>Calcium channel blocker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

